1 |
ADH1A
| 9件: Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease | D00707
D00707
|
Fomepizole
| 1件: 301 301 |
2 |
ADH1B
| 9件: Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease | D00707
D00707
|
Fomepizole
| 1件: 301 301 |
3 |
CPT1C
| 7件: Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Glucagon signaling pathway, Alcoholic liver disease | D05442
D05442
|
Perhexiline
| 2件: 58 58, 272 |
4 |
CPT1C
| 7件: Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Glucagon signaling pathway, Alcoholic liver disease | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
5 |
ADH1C
| 9件: Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease | D00707
D00707
|
Fomepizole
| 1件: 301 301 |
6 |
CPT1A
| 8件: Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Glucagon signaling pathway, Insulin resistance, Alcoholic liver disease | D05442
D05442
|
Perhexiline
| 2件: 58 58, 272 |
7 |
CPT1A
| 8件: Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Glucagon signaling pathway, Insulin resistance, Alcoholic liver disease | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
8 |
CPT1B
| 9件: Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Glucagon signaling pathway, Insulin resistance, Alcoholic liver disease, Diabetic cardiomyopathy | D05442
D05442
|
Perhexiline
| 2件: 58 58, 272 |
9 |
CPT1B
| 9件: Fatty acid degradation Fatty acid degradation, Fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, Thermogenesis, Glucagon signaling pathway, Insulin resistance, Alcoholic liver disease, Diabetic cardiomyopathy | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
10 |
MAPK14
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
11 |
MAPK14
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
12 |
IL17RA
| 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Alcoholic liver disease | D10061
D10061
|
Brodalumab
| 2件: 37 37, 51 |
13 |
IFNA1
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
14 |
IFNA1
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
15 |
IFNA2
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
16 |
IFNA2
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
17 |
IFNA4
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
18 |
IFNA4
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
19 |
IFNA5
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
20 |
IFNA5
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
21 |
IFNA6
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
22 |
IFNA6
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
23 |
IFNA7
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
24 |
IFNA7
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
25 |
IFNA8
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
26 |
IFNA8
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
27 |
IFNA10
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
28 |
IFNA10
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
29 |
IFNA13
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
30 |
IFNA13
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
31 |
IFNA14
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
32 |
IFNA14
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
33 |
IFNA16
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
34 |
IFNA16
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
35 |
IFNA17
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
36 |
IFNA17
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
37 |
IFNA21
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
38 |
IFNA21
| 25件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
39 |
IL1B
| 42件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
40 |
IL1B
| 42件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
41 |
IL1B
| 42件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09315
D09315
|
Canakinumab
| 10件: 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
42 |
IL1B
| 42件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09911
D09911
|
Gevokizumab
| 4件: 41 41, 50, 56, 269 |
43 |
IL6
| 49件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
44 |
IL6
| 49件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D08976
D08976
|
Pomalidomide
| 6件: 28 28, 34, 51, 85, 227, 331 |
45 |
IL6
| 49件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D09669
D09669
|
Siltuximab
| 2件: 28 28, 331 |
46 |
IL6
| 49件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D10080
D10080
|
Sirukumab
| 2件: 41 41, 46 |
47 |
IL12A
| 24件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| 17件: 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
48 |
IL12B
| 24件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| 17件: 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
49 |
IL17A
| 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D09967
D09967
|
Secukinumab
| 8件: 13 13, 37, 41, 46, 107, 160, 269, 271 |
50 |
IL17A
| 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D10071
D10071
|
Ixekizumab
| 6件: 36 36, 37, 107, 162, 269, 271 |
51 |
IL17A
| 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D11127
D11127
|
Tibulizumab
| 1件: 53 53 |
52 |
IL17A
| 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | D11550
D11550
|
Bimekizumab
| 3件: 46 46, 97, 271 |
53 |
MAP3K5
| 20件: Platinum drug resistance Platinum drug resistance, MAPK signaling pathway, Sphingolipid signaling pathway, Protein processing in endoplasmic reticulum, Apoptosis, Tight junction, TNF signaling pathway, Thermogenesis, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - reactive oxygen species, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10988
D10988
|
Selonsertib
| 1件: 86 86 |
54 |
NFKB1
| 73件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Ras signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Longevity regulating pathway, Cellular senescence, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D01146
D01146
|
Iguratimod
| 4件: 46 46, 51, 53, 271 |
55 |
PPARA
| 9件: PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D00565
D00565
|
Fenofibrate
| 5件: 8 8, 79, 93, 94, 265 |
56 |
PPARA
| 9件: PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D01366
D01366
|
Bezafibrate
| 7件: 20 20, 93, 94, 160, 296, 316, 324 |
57 |
PPARA
| 9件: PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D10711
D10711
|
Pemafibrate
| 1件: 93 93 |
58 |
PPARA
| 9件: PPAR signaling pathway PPAR signaling pathway, cAMP signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hepatitis C, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy | D11208
D11208
|
Elafibranor
| 1件: 93 93 |
59 |
PRKAA1
| 19件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
60 |
PRKAA1
| 19件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
61 |
PRKAA2
| 19件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
62 |
PRKAA2
| 19件: FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
63 |
MAPK11
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
64 |
MAPK11
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
65 |
MAPK13
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
66 |
MAPK13
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
67 |
RELA
| 73件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Ras signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Apoptosis, Longevity regulating pathway, Cellular senescence, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D12181
D12181
|
Edasalonexent
| 1件: 113 113 |
68 |
MAPK12
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
69 |
MAPK12
| 60件: Endocrine resistance Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, Cellular senescence, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Alcoholic liver disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
70 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00742
D00742
|
Etanercept
| 17件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
71 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00754
D00754
|
Thalidomide
| 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
72 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
73 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02597
D02597
|
Adalimumab
| 18件: 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 |
74 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
75 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
76 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D04358
D04358
|
Golimumab
| 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
77 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D04687
D04687
|
Lenalidomide
| 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
78 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D05393
D05393
|
Pegsunercept
| 1件: 46 46 |
79 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D08976
D08976
|
Pomalidomide
| 6件: 28 28, 34, 51, 85, 227, 331 |
80 |
TNF
| 64件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D09944
D09944
|
Ozoralizumab
| 1件: 46 46 |
81 |
C3
| 17件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phagosome, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Shigellosis, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, Staphylococcus aureus infection, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Viral carcinogenesis, Systemic lupus erythematosus | D11613
D11613
|
Pegcetacoplan
| 3件: 2 2, 62, 222 |
82 |
C5
| 10件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D03940
D03940
|
Eculizumab
| 7件: 11 11, 13, 14, 61, 62, 109, 222 |
83 |
C5
| 10件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11054
D11054
|
Ravulizumab
| 7件: 2 2, 11, 13, 50, 62, 66, 109 |
84 |
C5
| 10件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11473
D11473
|
Nomacopan
| 3件: 62 62, 109, 162 |
85 |
C5
| 10件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11477
D11477
|
Pozelimab
| 2件: 11 11, 62 |
86 |
C5
| 10件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11696
D11696
|
Crovalimab
| 2件: 62 62, 109 |
87 |
C5
| 10件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus | D11838
D11838
|
Vilobelimab
| 3件: 43 43, 44, 269 |
88 |
C5AR1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Staphylococcus aureus infection, Coronavirus disease - COVID-19 | D11093
D11093
|
Avacopan
| 3件: 43 43, 44, 222 |